Animal Models in Cardiovascular Research
David R. Gross

Animal Models in Cardiovascular Research

Third Edition

Springer
To Drs. Theodore S. Gross and Jeffrey M. Gross who continue the family obsession for the acquisition and dissemination of new knowledge.
This new edition of *Animal Models in Cardiovascular Research* describes historical and recent advances in our understanding of the cardiovascular system from studies conducted in a variety of animal models. Since the last edition, we have witnessed an explosion in the use of both congenic and transgenic animals. The use of specific knock-in and knock-out transgenic models has resulted in an avalanche of genetic, molecular, and protein-based information that, potentially, could result in an amazing new array of treatment and management options. However, the results of these studies also introduce a sometime bewildering array of redundant, overlapping, and competing molecular pathways involved in both physiological and pathological responses.

This third edition is designed to provide a better basis for understanding and using animal models in the current climate of background knowledge and information. It is significantly different than the previous two editions. Chapter 1 is updated from the previous editions addressing general principles of animal selection. It also provides expanded tables of normal physiological values for easy reference. Chapter 2 covers preoperative care, preanesthesia, and chemical restraint, and includes a significantly expanded section on pain recognition and analgesia particularly in rodents. Chapter 3 provides a summary of normal cardiovascular parameters obtained from intact, awake animals. The data have been rearranged in outline rather than the previous tabular form hopefully resulting in easier reference.

Chapter 4 addresses the techniques, problems, and pitfalls of measuring cardiac function in animals. There is an emphasis on the proper use of these measurements to develop new treatment and management strategies as well as using them to study mechanisms of disease. Chapter 5 emphasizes the techniques, problems, and pitfalls involved in the measurement of arterial function and ventricular/arterial coupling dynamics. Again the emphasis is on the use of these parameters to develop new treatment and management strategies and for studying the mechanisms of disease. Chapter 6 is an all new chapter dealing specifically with the problems and pitfalls inherent in using isolated heart preparations. The need for this chapter became apparent because so much information was published using obviously non-physiologic preparations. The use of both pumping and nonpumping preparations is described along with techniques necessary for using hearts from larger species where oxygen-carrying capacity of the perfusate is critical. The importance of hypoxia and anoxia in the interpretation of results is discussed.
Chapter 7 focuses on the cardiovascular effects of the postoperative analgesic drugs commonly used today and how to avoid potential problems resulting from these effects when reporting experimental data. These data are also presented in outline form rather than the tabular format used in the two previous editions. Chapter 8 addresses the use of naturally occurring animal models of valvular and infectious cardiovascular disease. The information presented has been updated and expanded from the second edition. Chapter 9 examines iatrogenic models of ischemic heart disease.

Chapter 10 is new. It provides a review of iatrogenic, transgenic, and naturally occurring animal models of cardiomyopathy and heart failure. Chapter 11 includes new, updated, and revised information reviewing iatrogenic and transgenic models of hypertension. Chapter 12 contains new and updated information on iatrogenic and transgenic models of atherosclerotic disease.

Chapter 13 is completely a new material dealing with animal models for the study of neurohumeral and central nervous system control of the cardiovascular system. Chapter 14 is also new. It provides examples of cardiovascular studies involving the use of specific transgenic models that are not normally associated with the cardiovascular system, such as estrogen receptor knockouts, to study cardiovascular function.

Urbana, IL

David R. Gross
Acknowledgements

Rosalie Gross has supported, encouraged, loved and endured since April of 1960. Our journey together continues.

Special thanks are owed to Professor Gary A. Iwamoto. Chapter 13 benefited significantly from his critical review and insightful suggestions.
Introduction

Animal rights activist organizations lobbied for and obtained significantly more restrictive regulations from governments worldwide since the last edition of this text. The agenda of most animal rights groups is to stop our use of animals. If biomedical science is to advance, we must understand the complexities and inter-relationships of the various physiological control mechanisms that regulate living whole animal systems. It is more essential than ever that we persevere.

“Old guard” physiologists, pharmacologists, and toxicologists, familiar with whole animal homeostatic control mechanisms, believe some “new breed” scientists working at the molecular level are so focused in their particular area of expertise they have little appreciation for the potential effects of the iatrogenic changes they induce on the whole animal. Frequently lost in the landslide of new information is an understanding of how any particular gene, molecule, and/or protein fits into our broad understanding of the basic physiology of the animal species and how that relates to the human species. A few scientists even seem unaware that most, if not all, physiological systems have multiple and redundant control mechanisms that adjust any particular organ or system behavior to the homeostatic requirements of the whole animal.

Physiological systems may have several stimulatory and inhibitory controls that operate at some constant level of activity. The same physiological response is therefore possible by increasing stimulation or decreasing inhibition or vice versa. At the molecular and cellular level, the more information we obtain the more apparent it becomes that multiple pathways are present to achieve the same response. When cells, or organ systems, are perturbed by interrupting, knocking out, or upregulating a specific molecular or genetic pathway, redundant pathway(s) are, appropriately, up- or downregulated in response to maintain homeostasis.

A significant number of the animal models described in this text have been derived using either congenic or transgenic techniques. It is therefore appropriate to provide an abbreviated description of how these animals are produced.

Congenic strains of animals are developed by mating two inbred strains and then backcrossing the descendants for at least five and up to ten or more generations with one of the original strains. At each step, selections are made for the specific phenotype or genotype of interest. This allows the phenotype or genotype to pass from the donor strain onto an otherwise uniform recipient strain. The congenic
strain can then be compared to the pure recipient strain to determine phenotypic or genetic differences. Producing large numbers of eggs via superovulation in females and then using microsatellite or nucleotide polymorphism markers to track the genes of interest can speed up specific congenic strain development.

Transgenic animals are generally created using one of two different protocols. The first uses recombinant DNA methodology to insert (knock in) or remove (knock out) a specific gene or protein from the genome. The DNA used usually includes a structural gene, as well as other sequences, that enables it to be incorporated into the DNA of the host and to be expressed by the particular cells of interest. The most common method of producing a transgenic animal model involves harvesting embryonic stem cells from the inner cell mass of blastocysts. When these cells are grown in culture, they retain their ability to produce all the cells of the mature animal. The cultured cells are then exposed to the DNA of interest and those cells that successfully incorporate the DNA are identified and separated. These isolated cells are then injected into the inner cell mass of blastocysts. The resulting embryos are transplanted into a pseudopregnant dam. It is uncommon, at least in mice, for more than a third of the embryos thus transplanted to develop into healthy offspring. The next step is to test all the offspring to identify those with the desired gene. Usually, no more than 10–20% will have that gene and they will be heterozygous for it. The next step is to mate two heterozygous mice and screen their offspring for the one in four that will be homozygous for the transgene of interest. Mating homozygous animals produces the transgenic strain.

A second method of producing transgenic animals involves the same preparation of the DNA of interest and then harvesting freshly fertilized eggs before the sperm head has become a pronucleus. The male pronucleus is injected with the DNA of interest, and when the pronuclei have fused to form diploid zygote nuclei, the zygote is allowed to divide by mitosis to form a two-cell embryo. The two-cell embryo is then implanted in the pseudopregnant foster mother and the same steps used in the embryonic stem cell method are followed.
Contents

1 General Principles of Animal Selection and Normal Physiological Values ................................................................. 1
   Special Requirement Considerations .................................................. 2
   Normal Physiological Data ................................................................ 3

2 Preanesthesia, Anesthesia, Chemical Restraint, and the Recognition and Treatment of Pain and Distress .......... 17
   General Principles of Pain Recognition in Animals ........................... 17
   The Use of Anti-Cholinergic Drugs for Preanesthesia ..................... 21
   General Comments on Preanesthetic Agents .................................. 22
   Preanesthesia and Anesthesia in Rats and Mice ............................... 22
   Chemical Restraint (Sedation) in Rats and Mice ............................... 23
   Pain and Distress Recognition in Rats and Mice .............................. 23
   Treatment of Pain in Rats and Mice ................................................ 26
      Local Anesthetic Agents ............................................................. 26
      Nonsteroidal Anti-Inflammatory Drugs ....................................... 26
      Narcotics ................................................................................... 26
   Preanesthesia and Anesthesia in Rabbits ........................................... 28
   Chemical Restraint (Sedation) in Rabbits ......................................... 29
   Pain Recognition in Rabbits ............................................................ 29
   Treatment of Pain in Rabbits ........................................................... 29
      Local Anesthetics .................................................................... 29
      Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) ....................... 30
      Narcotics .................................................................................. 30
      Alpha–Agonists ....................................................................... 30
   Preanesthesia and Anesthesia in Dogs .............................................. 30
   Chemical Restraint (Sedation) in Dogs ............................................. 32
   Pain Recognition in Dogs ............................................................... 33
   Treatment of Pain in Dogs .............................................................. 34
      Local Anesthetics .................................................................... 34
      NSAIDs .................................................................................. 34
      Narcotics .................................................................................. 34
      Alpha-Agonists ....................................................................... 35
3 Normal Cardiac Function Parameters

Preanesthesia and Anesthesia in Cats ......................................................... 35
Chemical Restraint (Sedation) in Cats .......................................................... 36
Pain Recognition in Cats ............................................................................ 37
Treatment of Pain in Cats ........................................................................... 37
  Local Anesthetics .................................................................................. 37
  NSAIDs ................................................................................................. 37
  Narcotics ................................................................................................ 37
  Alpha-Agonists ...................................................................................... 38
Preanesthesia and Anesthesia in Guinea Pigs ............................................. 38
Chemical Restraint (Sedation) in Guinea Pigs ............................................. 38
Pain Recognition in Guinea Pigs ................................................................. 38
Treatment of Pain in Guinea Pigs ................................................................. 39
  Local Anesthetic Agents ........................................................................ 39
  NSAIDs ................................................................................................. 39
  Narcotics ................................................................................................ 39
  Alpha-Agonists ...................................................................................... 39
Preanesthesia and Anesthesia in Pigs .......................................................... 39
Chemical Restraint (Sedation) in Pigs .......................................................... 41
Pain Recognition in Pigs ............................................................................ 41
Treatment of Pain in Pigs ........................................................................... 41
  Local Anesthetic Agents ........................................................................ 41
  NSAIDs ................................................................................................. 42
  Narcotics ................................................................................................ 42
  Alpha-Agonists ...................................................................................... 42
Preanesthesia and Anesthesia in Calves, Sheep, and Goats ........................ 42
Chemical Restraint (Sedation) in Small Ruminants ..................................... 43
Recognition of Pain in Small Ruminants ..................................................... 43
Treatment of Pain in Small Ruminants ......................................................... 44
  Local Anesthetic Agents ........................................................................ 44
  NSAIDs ................................................................................................. 44
  Narcotics ................................................................................................ 44
  Alpha-Agonists ...................................................................................... 44
Preanesthesia and Anesthesia in Rhesus Monkeys ...................................... 45
Chemical Restraint (Sedation) in Rhesus Monkeys ...................................... 45
Pain Recognition in Rhesus Monkeys ........................................................ 45
Treatment of Pain in Rhesus Monkeys ......................................................... 46
  Local Anesthetics .................................................................................. 46
  NSAIDs ................................................................................................. 46
  Narcotics ................................................................................................ 46
Conclusions .................................................................................................. 47

3 Normal Cardiac Function Parameters

3 Normal Cardiac Function Parameters
4 Measuring Cardiac Function

The Pressure–Volume Relationship................................................................. 67
Another Measure of Ventricular Elasticity .................................................... 68
Measurement of Electrical Activity ................................................................. 68
Measurement of Pressure ............................................................................. 69
Echocardiography........................................................................................... 70
  History ....................................................................................................... 70
  Physics of Echo Technology .................................................................. 72
Doppler Flow Velocity and Tissue Doppler Imaging ...................................... 74
  History ................................................................................................... 74
  Physics of Doppler Technology ............................................................. 75
Tissue Doppler Imaging............................................................................... 76
Examples of Ultrasound Data Reported Using
<20-MHz Transducers............................................................................... 77
Examples of Ultrasound Data Reported Using 20-MHz
(or Greater) Transducers........................................................................... 78
Summary of Information Needed to Ascertain
the Reliability of Ultrasound Data.............................................................. 80
Techniques for Measuring Ventricular Volumes ........................................ 80
  Radiographic .......................................................................................... 80
  Echocardiography and Tissue Doppler Imaging .................................... 81
  Sonomicrometry .................................................................................... 81
  Radionuclide Ventriculography .............................................................. 81
  Magnetic Resonance Imaging and Computer-Assisted
  Tomography Scan ................................................................................... 82
  Conductance-Derived Volume Measurements ........................................ 82
Other Measures of Myocardial Physical Properties ................................... 84
  Myocardial Resistivity ......................................................................... 85
  Tissue Characterization ........................................................................ 85
Measuring Diastolic Dysfunction ................................................................. 86

5 Measuring Vascular Function and Ventricular/
Arterial Coupling Dynamics ..................................................................... 93

History ........................................................................................................ 93
Quantification of Arterial Compliance ........................................................ 94
Force-Displacement Measurements ........................................................... 95
Pulse Wave Velocity .................................................................................... 97
Modeling Techniques for Estimating Vascular Mechanical Behavior ...... 99
Ventricular/Vascular Coupling ................................................................. 101
  Ventricular/Vascular Coupling Determined Using
  the Input Impedance ............................................................................. 101
  Ventricular/Vascular Coupling Determined Using
  the Ratio of Ventricular End-Systolic Pressure
  and Stroke Volume ($P_{es}/SV$) Designated $E_a$ .................................... 102
Diastolic Ventricular/Vascular Coupling ............................................... 104
MRI Imaging for Detection of Ventricular/Vascular Coupling ............... 104
Tissue Doppler Imaging and Elasticity Imaging ........................................ 104

6 Isolated Heart Preparations, Problems, and Pitfalls ......................... 109

Development of the Isolated Heart Preparation ................................... 109
Retrograde Perfusion Preparations (The Langendorff Preparation) .......... 112
Choosing between the Pressure-Regulated or Flow-Regulated
Langendorff-Type Preparation ............................................................... 114
The Isolated, Working, In Situ Heart-Lung Preparation ......................... 114
The Isolated Working Left Heart Preparation ........................................ 114
The Langendorff-Type Perfused Working Left Heart Preparation ............ 115
The Biventricular Isolated Working Heart Preparation ......................... 117
The Biventricular, Retrograde-Perfused, Working Heart Preparation ......... 119
Perfusion Solutions ............................................................................... 120
Support Animals .................................................................................. 122
Washed Red Blood Cell Addition to the Perfusate ................................ 122
Problems and Pitfalls .......................................................................... 123
  Exclusion Criteria ............................................................................... 123
  Problems Common to Crystalloid Perfusion ........................................ 124
  Contamination ................................................................................... 124
  Temperature ....................................................................................... 125
  Metabolic “Poisoning” ....................................................................... 125
  Pacing vs. Spontaneously Beating Preparations ................................... 125
  Frequency Response Testing of Ventricular Pressure
  Recording Systems .............................................................................. 126
  Heterotopic Transplants ..................................................................... 126

7 Cardiovascular Effects of Anesthetics, Sedatives, Postoperative Analgesic Agents, and Other Pharmaceuticals .......... 131

  Barbiturates ..................................................................................... 131
  Propofol .......................................................................................... 132
  α-Chloralose .................................................................................... 133
  Urethane ........................................................................................ 134
  α-Chloralose + Urethane .................................................................... 134
  Steroid Anesthetic Agents .................................................................. 134
  Inhalation Anesthetic Agents ............................................................. 135
    General ......................................................................................... 135
    Halothane .................................................................................... 136
    Isoflurane ................................................................................... 137
    Desflurane .................................................................................. 138
    Sevoflurane ................................................................................ 139
    Ether ............................................................................................ 140
    Nitrous Oxide .............................................................................. 140
Contents

Trichloroethylene ................................................................. 140
The Opioids ................................................................................. 141
  Morphine .................................................................................. 141
  Meperidine (Demerol) .............................................................. 144
  Methadone ................................................................................ 144
  Levomethadone ................................................................. 145
  Pentazocine ............................................................................ 145
  Fentanyl .................................................................................. 145
  Butorphanol ............................................................................ 147
  Buprenorphine ....................................................................... 147
  Oxymorphone ......................................................................... 148
  Naloxone ............................................................................... 148
  Other Synthetic Opioids ......................................................... 149
Dissociative Anesthetic Agents ............................................. 150
  Ketamine ................................................................................ 150
  Tiletamaine .......................................................................... 151
Imidazole and Other Hypnotic, Amnesiac, Anxiolytic, or Antipsychotic Compounds ......................................................... 152
  Etomidate ............................................................................ 152
  Metomidate .......................................................................... 153
  Benzodiazepines .................................................................. 153
  Rilmenidene .......................................................................... 155
  α-2 Adrenergic Receptor Agonists ........................................... 156
    Medetomidine and Dexmedetomidine ................................ 156
  Clonidine ............................................................................ 157
  β-2-Adrenergic Receptor Agonists ......................................... 157
    Clenbuterol ......................................................................... 157
    KUR-1246 .......................................................................... 158
    Fenoterol ............................................................................ 158
  Rauwolfia Derivatives .......................................................... 158
    Reserpine ............................................................................ 158
  Phenothiazine Derivatives ..................................................... 160
    Chlorpromazine and Promazine ........................................ 160
    Acetylpmazine (Acepromazine) .......................................... 162
  Other Phenothiazine Derivatives .......................................... 163
    Triflupromazine, Levomepromazine, Prochlorperazine (thioridazine), Cyamemazine ........................................ 163
  Butyrophenones .................................................................... 164
    Droperidol ........................................................................ 164
    Haloperidol ........................................................................ 165
    Azerperone ...................................................................... 166
  Other Antipsychotic/Anxiolytic/Antidepressant (Tranquilizer) Drugs .......................................................... 166
    Tricyclic Antidepressants ................................................... 167
    Selective Serotonin Uptake Inhibitors ............................... 167
### Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Atypical Antipsychotics</td>
<td>169</td>
</tr>
<tr>
<td>Sertindole</td>
<td>169</td>
</tr>
<tr>
<td>Pimozide</td>
<td>169</td>
</tr>
<tr>
<td>Clozapine</td>
<td>169</td>
</tr>
<tr>
<td>Risperidone</td>
<td>170</td>
</tr>
<tr>
<td>Amisulpride</td>
<td>170</td>
</tr>
<tr>
<td>Minaprine</td>
<td>171</td>
</tr>
<tr>
<td>Atypical Antipsychotics</td>
<td>171</td>
</tr>
<tr>
<td>Aripiprazole</td>
<td>171</td>
</tr>
<tr>
<td>Fezolamine</td>
<td>171</td>
</tr>
<tr>
<td>Olanzapine</td>
<td>171</td>
</tr>
<tr>
<td>Lortalamine</td>
<td>171</td>
</tr>
<tr>
<td>Xylazine</td>
<td>172</td>
</tr>
<tr>
<td>Drugs in Combination Providing Neurolept Analgesia/Anesthesia</td>
<td>172</td>
</tr>
<tr>
<td>Metomidate + Azaperone</td>
<td>172</td>
</tr>
<tr>
<td>Medetomidine + Butorphanol</td>
<td>173</td>
</tr>
<tr>
<td>Medetomidine + Butorphanol + Midazolam</td>
<td>173</td>
</tr>
<tr>
<td>Medetomidine + Buprenorphine + Ketamine</td>
<td>173</td>
</tr>
<tr>
<td>Medetomidine + Midazolam</td>
<td>174</td>
</tr>
<tr>
<td>Medetomidine + Hydromorphone</td>
<td>174</td>
</tr>
<tr>
<td>Dexmedetomidine + Butorphanol</td>
<td>174</td>
</tr>
<tr>
<td>Medetomidine + Ketamine</td>
<td>174</td>
</tr>
<tr>
<td>Medetomidine + Ketamine + Midazolam</td>
<td>175</td>
</tr>
<tr>
<td>Dexmedetomidine + Ketamine</td>
<td>175</td>
</tr>
<tr>
<td>Ketamine in Combination with Tranquilizers</td>
<td>175</td>
</tr>
<tr>
<td>Ketamine + Acepromazine</td>
<td>175</td>
</tr>
<tr>
<td>Ketamine + Xylazine</td>
<td>176</td>
</tr>
<tr>
<td>Ketamine + Xylazine + Guaiifenesin</td>
<td>178</td>
</tr>
<tr>
<td>Ketamine + Xylazine + Buprenorphine</td>
<td>178</td>
</tr>
<tr>
<td>Ketamine + Diazepam</td>
<td>178</td>
</tr>
<tr>
<td>Midazolam + Butorphanol</td>
<td>179</td>
</tr>
<tr>
<td>Midazolam + Fentanyl + Fluanisone</td>
<td>179</td>
</tr>
<tr>
<td>Midazolam + Methadone + Propofol + Isoflurane + Continuous Infusion of Propofol and Fentanyl</td>
<td>179</td>
</tr>
<tr>
<td>Acepromazine + Meperidine</td>
<td>179</td>
</tr>
<tr>
<td>Fentanyl + Droperidol (Innovar-Vet®)</td>
<td>180</td>
</tr>
<tr>
<td>Azaperone + Metomidate</td>
<td>180</td>
</tr>
<tr>
<td>Acepromazine + Etorphine</td>
<td>180</td>
</tr>
<tr>
<td>Fentanyl + Morphine</td>
<td>180</td>
</tr>
<tr>
<td>Fentanyl + Propofol</td>
<td>181</td>
</tr>
<tr>
<td>Xylazine + Morphine</td>
<td>181</td>
</tr>
<tr>
<td>Oxymorphone + Bupivacaine</td>
<td>181</td>
</tr>
<tr>
<td>Tiletamine + Zolazepam (Telazol®, Zoletil®)</td>
<td>181</td>
</tr>
<tr>
<td>Local Anesthetic Agents</td>
<td>182</td>
</tr>
<tr>
<td>Non-steroidal Anti-inflammatory Agents</td>
<td>183</td>
</tr>
</tbody>
</table>
8 Naturally Occurring and Iatrogenic Animal Models of Valvular, Infectious, and Arrhythmic Cardiovascular Disease

Congenital Cardiac Defects, General Information ............................................. 203
Genetically Engineered Models, General Information ................................ 204
Naturally Occurring Models of Valvular Disease ......................................... 205
Iatrogenic Models of Valvular Disease ............................................................. 207
Infectious Cardiovascular Disease ................................................................. 208
  Bartonella sp ............................................................................................. 208
  Borrelia sp ................................................................................................. 208
  Coxsackievirus sp ..................................................................................... 209
Diphtheritic Myocarditis .................................................................................. 209
Encephalomyocarditis Virus ............................................................................ 210
Autoimmune Myocarditis ............................................................................. 210
  Infectious Complications Following Burn Injury ...................................... 210
Arrhythmic Cardiovascular Disease ................................................................. 211
  Naturally Occurring Cardiac Arrhythmias .................................................. 211
  Iatrogenic Cardiac Arrhythmias ................................................................. 211

9 Iatrogenic Models of Ischemic Heart Disease ................................................. 219

Global Ischemia ............................................................................................. 219
Regional Ischemia .......................................................................................... 221

10 Iatrogenic, Transgenic, and Naturally Occurring Models of Cardiomyopathy and Heart Failure ................................................................. 231

Naturally Occurring Models of Cardiomyopathy ........................................... 232
  Heritable HCM in Cats ............................................................................... 232
  DCM in Dogs ............................................................................................... 233
Cattle with Cardiomyopathy and Woolly Hair Coat Syndrome ...................... 234
Primates ......................................................................................................... 235
Whales .......................................................................................................... 235
Iatrogenic Models of Cardiomyopathy and Heart Failure ................................ 235
  Ventricular Arrhythmia ............................................................................... 235
  Increasing the Ventricular Workload ......................................................... 236
  Rapid Cardiac Pacing .................................................................................. 236
  Pressure Overload ....................................................................................... 236
  Volume Overload ........................................................................................ 237
  Valvular Stenoses or Insufficiencies ............................................................ 237
## Contents

Other Iatrogenic Models of Cardiomyopathy and Heart Failure ............. 237  
  Anthracycline-Induced Cardiomyopathy.................................................. 237  
  Diabetic and Lipid-Toxic Models of Cardiomyopathy .......................... 238  
  Chronic Myocardial Ischemia Models of Cardiomyopathy............... 238  
  Toxocosis and Mineral-Deficient Models of Cardiomyopathy......... 239  
  Autoimmune Models of Cardiomyopathy ........................................... 239  
  Hyperthyroid and Hyper-Adrenergic Models of Cardiomyopathy...... 240  
  Chronic Hypoxia Models of Cardiomyopathy........................................ 240  
  Liver Cirrhosis Models of Cardiomyopathy .................................... 240  
  Murine Cysticercosis Model of Cardiomyopathy......................... 240  
  Commercially Available Inbred-Rat Models of Cardiomyopathy and Heart Failure ................................................. 240  
  Transgenic Models of Cardiomyopathy and Heart Failure .............. 241  
  Mouse and Rat Models of Familial Hypertrophic Cardiomyopathy and HCM .......................................................... 241  
  Mouse and Rat Models of DCM .......................................................... 242  
  Overexpression Models........................................................................ 245

### 11 Iatrogenic, Congenic, and Transgenic Models of Hypertension....... 259

  Renovascular Hypertension .................................................................. 260  
  2K1C and 1K1C Renovascular Hypertension in Rats.......................... 261  
  2K1C and 1K1C Renovascular Hypertension Models in Mice............. 263  
  Renovascular Hypertension Models in Rabbits ................................ 264  
  1K1C Renovascular Hypertension in Dogs ........................................ 265  
  Renovascular Hypertension in Pigs .................................................... 265  
  Genetic Models of Hypertension .......................................................... 266  
  Spontaneously Hypertensive Rat ....................................................... 266  
  Stroke-Prone SHR............................................................................ 269  
  Dahl Salt-Sensitive and Insensitive Rats .......................................... 270  
    Other Salt-Sensitive (Salt-Induced) Models of Hypertension ........... 272  
  Angiotensin-II-Induced Hypertension ................................................. 273  
  DOCA-Induced Hypertension .............................................................. 276  
  NO-Synthesis Blockade Hypertension ............................................... 278  
  Glucocorticoid-Induced Hypertension .............................................. 280  
  Intrauterine Growth-Restricted Induced Hypertension ..................... 281  
  Other Transgenic and Congenic Models of Hypertension ................. 283  
    The mRen-2 Model ....................................................................... 283  
    ATR-1 Models ............................................................................. 283  
    Angio-II Overexpression Models..................................................... 284  
    G-Protein Models ........................................................................ 284  
    eNOS Models ............................................................................... 285  
    Endothelin Models ........................................................................ 285  
    Chromogranin-A Models ............................................................... 286  
    PPAR-α Models .......................................................................... 286
Bradykinin-2 Models ................................................................. 286
Estrogen Models ....................................................................... 287
Corin Models ............................................................................. 287
Vitamin D Receptor Models ....................................................... 287
Glucocorticoid Receptor Models ............................................... 287
Smoothelin Models .................................................................... 288
Adiponectin Models .................................................................... 288
Aryl Hydrocarbon Models .......................................................... 288
Parathyroid Hormone Type 1 Receptor Models ......................... 289
Profilin Models .......................................................................... 289
Oligodeoxynucleotide Models .................................................... 289
Multiple Transgenic Models ....................................................... 290
Congenic Models ......................................................................... 290
Other Models of Systemic Hypertension .................................... 291
Pulmonary Hypertension ............................................................. 292
Hypoxia-Induced Pulmonary Hypertension ................................ 292
Monocrotaline-Induced Pulmonary Hypertension ....................... 293
Transgenic Models of Pulmonary Hypertension ....................... 294

12 Naturally Occurring, Iatrogenic and Transgenic Models of Atherosclerotic Disease ...................................................... 307
Characteristics of Plaque Rupture and Resulting Thrombosis .......... 309
Implication of New “Players” in the Pathogenesis of Atherosclerotic Disease ......................................................... 309
Animal Models ......................................................................... 310
Naturally Occurring Animal Models of Atherosclerosis ............... 311
Primate Models of Atherosclerosis ............................................ 311
Swine Models of Atherosclerosis ............................................... 312
Dog and Cat Models .................................................................. 312
Rabbit Models ........................................................................... 313
Transgenic Rabbit Models .......................................................... 314
Rat Models ............................................................................... 315
Transgenic Rat Models .............................................................. 317
Mouse Models ........................................................................... 317
Mice Models of Glucose Intolerance ........................................... 317
Graft Vasculopathy .................................................................... 323
Hamsters .................................................................................. 324
Sand Rats ................................................................................ 324

13 Animal Models for the Study of Neurohumeral and Central Neural Control of the Cardiovascular System .............. 331
The Autonomic Nervous System in Blood Pressure Homeostasis and Cardiorespiratory Reflex Responses ................ 333
Rostal and Caudal Ventrolateral Medulla .................................... 334
<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nucleus Tractus Solitarius</td>
<td>337</td>
</tr>
<tr>
<td>Hypothalamic Paraventricular Nucleus</td>
<td>339</td>
</tr>
<tr>
<td>Periaqueductal Gray</td>
<td>340</td>
</tr>
<tr>
<td>Anterior and Posterior Hypothalamic Areas</td>
<td>342</td>
</tr>
<tr>
<td>Median Preoptic Nucleus</td>
<td>342</td>
</tr>
<tr>
<td>Nucleus Cuneatus</td>
<td>342</td>
</tr>
<tr>
<td>Lateral Parabrachial Nucleus and the Dorsal Raphe Nucleus</td>
<td>343</td>
</tr>
<tr>
<td>Caudal Vestibular Nucleus</td>
<td>343</td>
</tr>
<tr>
<td>Gender Effects on Central Control of Cardiovascular Responses</td>
<td>343</td>
</tr>
<tr>
<td>Neurohumeral Control</td>
<td>344</td>
</tr>
<tr>
<td>Renin-Angiotensin System</td>
<td>344</td>
</tr>
<tr>
<td>Serotonin</td>
<td>344</td>
</tr>
<tr>
<td>Vasopressin</td>
<td>345</td>
</tr>
<tr>
<td>Endogenous Ouabain-Like Substance</td>
<td>345</td>
</tr>
<tr>
<td>Opioids</td>
<td>345</td>
</tr>
<tr>
<td>Tyrosine Hydroxylase and Phenylethanolamine</td>
<td>346</td>
</tr>
<tr>
<td>N-Methyltransferase</td>
<td>346</td>
</tr>
<tr>
<td>Neuropeptide Y</td>
<td>346</td>
</tr>
<tr>
<td>Leptin</td>
<td>346</td>
</tr>
<tr>
<td>Dopamine-β-Hydroxylase</td>
<td>346</td>
</tr>
<tr>
<td>11-β-Hydroxylase and Aldosterone Synthase</td>
<td>347</td>
</tr>
<tr>
<td>Orexin</td>
<td>347</td>
</tr>
<tr>
<td>Urotensin-II</td>
<td>347</td>
</tr>
<tr>
<td>Cholecystokinin</td>
<td>348</td>
</tr>
</tbody>
</table>

14 Other Transgenic Animal Models Used in Cardiovascular Studies

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex-Related Responses</td>
<td>356</td>
</tr>
<tr>
<td>Kinases</td>
<td>357</td>
</tr>
<tr>
<td>Oxidases and Oxygenases</td>
<td>358</td>
</tr>
<tr>
<td>Adenosine and Adrenergic Receptors</td>
<td>359</td>
</tr>
<tr>
<td>Nitric Oxide Synthase</td>
<td>360</td>
</tr>
<tr>
<td>Metabolic Syndrome</td>
<td>361</td>
</tr>
<tr>
<td>Xenotransplantation</td>
<td>362</td>
</tr>
<tr>
<td>Na+/Ca²⁺ and Na+/H⁺ Exchangers</td>
<td>364</td>
</tr>
<tr>
<td>Inflammatory Cytokines</td>
<td>365</td>
</tr>
<tr>
<td>Peroxisome Proliferator-Activated Receptor</td>
<td>366</td>
</tr>
<tr>
<td>Renin-Angiotensin System</td>
<td>366</td>
</tr>
<tr>
<td>Bradykinin-2 Receptor</td>
<td>367</td>
</tr>
<tr>
<td>Apolipoprotein-E and Low-Density Lipoprotein</td>
<td>367</td>
</tr>
<tr>
<td>Knockout Models</td>
<td>367</td>
</tr>
<tr>
<td>Toll-Like Receptors</td>
<td>368</td>
</tr>
<tr>
<td>Caveolin-1 (Cav-1)</td>
<td>368</td>
</tr>
<tr>
<td>Long QT Syndrome</td>
<td>369</td>
</tr>
<tr>
<td>Topic</td>
<td>Page</td>
</tr>
<tr>
<td>----------------------------------------------------------------------</td>
<td>------</td>
</tr>
<tr>
<td>Nuclear Factor Kappa-B</td>
<td>369</td>
</tr>
<tr>
<td>Orphan Nuclear Receptors</td>
<td>370</td>
</tr>
<tr>
<td>Troponin</td>
<td>370</td>
</tr>
<tr>
<td>Chromogranin A</td>
<td>371</td>
</tr>
<tr>
<td>Lectin-Like Oxidized Low-Density Lipoprotein Receptor</td>
<td>371</td>
</tr>
<tr>
<td>Junctin</td>
<td>371</td>
</tr>
<tr>
<td>Connexin</td>
<td>372</td>
</tr>
<tr>
<td>Phospholamban</td>
<td>372</td>
</tr>
<tr>
<td>Fas Ligand</td>
<td>373</td>
</tr>
<tr>
<td>Proteases, Metalloproteinases, and ATPases</td>
<td>373</td>
</tr>
<tr>
<td>Binary Calsequestrin/P2Xr-Purinergic Receptor (CSQ/P2X4R) Transgenics</td>
<td>374</td>
</tr>
<tr>
<td>pro-ANP Gene Disrupted Mouse</td>
<td>375</td>
</tr>
<tr>
<td>Macrophage Colony-Stimulating Factor</td>
<td>375</td>
</tr>
<tr>
<td>Endothelin-1</td>
<td>375</td>
</tr>
<tr>
<td>Elastin</td>
<td>376</td>
</tr>
<tr>
<td>α-2-Antiplasmin</td>
<td>376</td>
</tr>
<tr>
<td>CAMP Response Element Binding Protein</td>
<td>376</td>
</tr>
<tr>
<td>Fatty Acid Transport Protein: CD36</td>
<td>376</td>
</tr>
<tr>
<td>Clotting Factor XIII</td>
<td>377</td>
</tr>
<tr>
<td>Apelin</td>
<td>377</td>
</tr>
<tr>
<td>T-Box Transcription Factor</td>
<td>377</td>
</tr>
<tr>
<td>Thrombospondin-1 and Its Receptor CD47</td>
<td>377</td>
</tr>
<tr>
<td>Polyomavirus Middle T Antigen</td>
<td>378</td>
</tr>
<tr>
<td>Thrombopoietin Receptor</td>
<td>378</td>
</tr>
<tr>
<td>Vascular Endothelial Growth Factor</td>
<td>378</td>
</tr>
<tr>
<td>Osteopontin</td>
<td>378</td>
</tr>
<tr>
<td>ATP-Binding Membrane Cassette Transporter-A1</td>
<td>379</td>
</tr>
<tr>
<td>The K+/Cl− Cotransporter KCC3</td>
<td>379</td>
</tr>
<tr>
<td>Aldosterone Synthase Overexpression</td>
<td>379</td>
</tr>
<tr>
<td>Cysteine and Glycine-Rich Protein-2 (CSRP-2)</td>
<td>379</td>
</tr>
<tr>
<td>Parathyroid Hormone Type-1 Receptor and PTH/PTH-Related Protein</td>
<td>380</td>
</tr>
<tr>
<td>Vitamin D Receptor</td>
<td>380</td>
</tr>
<tr>
<td>Thromboxane Receptor (Tp)</td>
<td>380</td>
</tr>
<tr>
<td>T and B Cells</td>
<td>380</td>
</tr>
<tr>
<td>Vanilloid Type-1 Receptors (TRPV-1)</td>
<td>381</td>
</tr>
<tr>
<td>Serotonin Transporter (SERT)</td>
<td>381</td>
</tr>
<tr>
<td>CC Chemokine Receptor-2 (CCR-2)</td>
<td>381</td>
</tr>
<tr>
<td>Thymosin β-4</td>
<td>381</td>
</tr>
</tbody>
</table>

Index ................................................................................................................ 393
Dr. David Gross entered private veterinary practice after earning the DVM degree from Colorado State University in 1960. In 1974 he was awarded the Ph.D. degree in physiology from the Ohio State University beginning a 36-year career in academics that culminated as professor and head of the Department of Veterinary Biosciences in the College of Veterinary Medicine, University of Illinois, Urbana-Champaign. Dr. Gross’ research career encompassed 58 funded projects totaling over $5.5 million and 91 papers published in refereed journals using a wide variety of animal models. Ironically, his three most-cited research papers received no external funding. He and his colleagues showed that feeding dietary cholesterol to rabbits induced Alzheimer’s-like lesions in the brain. Their work also showed that surgery involving cardiopulmonary bypass resulted in Alzheimer’s-like brain lesions in pigs. With another group of colleagues, he helped pioneer minimally invasive coronary artery bypass grafting techniques using the pig as a model.